Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Hematol Rep. 2005 Jan;4(1):7-14.

Treatment of diffuse large B-cell lymphoma.

Author information

  • 1Hematology Department, Centre Hospitalier Lyon Sud, 69495 Pierre-Benite, Lyon, France. bertrand.coiffier@chu-lyon.fr

Abstract

A review of new or emerging ideas concerning diffuse large B-cell lymphomas (DLBCL) is presented with particular emphasis on histologic classification, genetic prognostic factors, and first-line treatments. This lymphoma rests the most heterogeneous of all lymphomas for its clinical characteristics and outcome. This heterogeneity is probably secondary to the fact that a large proportion seems to occur from a transformation of an unknown indolent lymphoma. Current treatment is based on the combination of chemotherapy including cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) or dose-intense CHOP-like regimen, and rituximab (R-CHOP).

PMID:
15610654
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center